Nimbus Therapeutics

Dr. George P. Vlasuk is a scientifically trained executive with nearly 40 years of leadership experience in drug discovery and development at small and large biotechnology and pharmaceutical companies. Dr. Vlasuk was previously President, CEO and CSO of Navitor Pharmaceuticals, Inc., and currently serves as a Board member and consultant. Dr. Vlasuk... also serves on the Boards of Nimbus Therapeutics and Riparian Pharmaceuticals as well as a consultant and scientific advisor to several biopharmaceutical companies. Before joining Navitor, Dr. Vlasuk served as CEO of Sirtris, a GlaxoSmithKline Company. Prior to Sirtris, Dr. Vlasuk was Vice President, Metabolic Disease and Hemophilia Research, at Wyeth Pharmaceuticals. Dr. Vlasuk also previously served as Chief Scientific Officer and Executive Vice President of Research and Development at Corvas International, prior to the merger of Corvas and Dendreon Corporation. Earlier in his career, Dr. Vlasuk led a research team at Merck and Co., and was responsible for multiple discovery programs in the field of cardiovascular medicine. George is the author of more than 100 peer-reviewed scientific publications, book chapters and reviews, and 38 issued U.S. and foreign patents. Nimbus Therapeutics is backed by world-class life science investors, including Atlas Venture, SR One, Lilly Ventures, Bill Gates, Pfizer Venture Investments, Lightstone Ventures, RA Capital and BVF Partners. The company closed a $24 million Series A financing in June 2011, a $43 million Series B financing in March 2015, an additional $65 million in financing in June 2018 and another $60 million in financing in October 2020.Read More